



The Liver Meeting

November 8-11, 2025; Washington, DC; Resource Hub – Draft

---

**Welcome to our resource hub for The Liver Meeting 2025!** This is a one-stop-shop for all your The Liver Meeting 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

### Table of Contents

[Useful Conference Links](#)

---

[Day-of Conference Reports](#)

---

[Top Highlights](#)

---

### Useful Conference Links

- [Conference Website](#)
- [Conference Registration](#)
- [Conference Program](#)

### Day-of Conference Reports

1. [Day #1 Highlights](#)
2. [Day #2 Highlights](#)
3. [Day #3 Highlights](#)
4. [Day #4 Highlights](#)

### Top Highlights

1. [President's Welcome](#) blends activism, public policy, and scientific advancement in hepatology
2. [Science at a crossroads](#): Dr. Francis Collins calls for rebuilding trust
3. [From clinic to Congress](#): Sen. Bill Cassidy's mission to eradicate Hepatitis C
4. [Expanding roles of resmetivrom](#): Dr. Naim Alkhouri on moving beyond at-risk MASH to cirrhosis, cardiovascular health, and high alcohol use
5. [GLP-1 RAs for steatotic liver disease](#): Semaglutide, tirzepatide, survodutide, and retatrutide, along with Madrigal's Rezdiffra
6. [Efruxifermin demonstrates improvements to multiple non-invasive tests](#) indicative of fibrosis regression in patients with compensated cirrhosis
7. [Real-world study shows that GLP-1 RAs improve liver-related outcomes](#) more than bariatric surgery in people with T2D and obesity
8. [Phase 2b trial of AstraZeneca's dual GLP-1/glucagon RA cotadutide](#) demonstrates MASH resolution, weight loss, and A1c improvement
9. [Post hoc analysis of the ESSENCE trial](#): Liver-related health benefits of semaglutide beyond weight loss
10. [M-ACCEL trial results](#): HU6, an oral controlled metabolic accelerator, reduces liver fat and improves adiposity markers in adults with MASH

11. [Hans Popper State of the Art Lecture](#): Hacking the hepatic lipid code – mechanisms and therapeutic opportunities in steatotic liver disease
12. [MASLD Debrief](#): A continued need for screening, referral, and therapeutics for the future
13. [Post hoc analysis of MAESTRO-NAFLD-1](#): Resmetirom treatment for two years led to significant improvement in patients with compensated MASH cirrhosis
14. [Mazdutide, a once-weekly dual GLP-1/glucagon RA, demonstrates remarkable efficacy](#) for the resolution of steatosis in over 60% of participants